Is OMER or NKTR more profitable?

Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Nektar Therapeutics' return on equity of -85.40% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -102.16% 64.87% Nektar Therapeutics -284.18% -85.40% -39.99%

Does the media favor OMER or NKTR?

In the previous week, Nektar Therapeutics had 6 more articles in the media than Omeros. MarketBeat recorded 9 mentions for Nektar Therapeutics and 3 mentions for Omeros. Omeros' average media sentiment score of 0.88 beat Nektar Therapeutics' score of 0.66 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OMER or PRGO more profitable?

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -102.16% 64.87% Perrigo -43.50% 9.96% 3.90%

Does the media prefer OMER or PRGO?

In the previous week, Omeros had 2 more articles in the media than Perrigo. MarketBeat recorded 3 mentions for Omeros and 1 mentions for Perrigo. Omeros' average media sentiment score of 0.88 beat Perrigo's score of -0.26 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is OMER or PCRX more profitable?

Pacira BioSciences has a net margin of 0.70% compared to Omeros' net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -102.16% 64.87% Pacira BioSciences 0.70% 10.24% 5.47%

Do analysts recommend CPIX or OMER?

Omeros has a consensus target price of $40.33, indicating a potential upside of 284.86%. Given Omeros' stronger consensus rating and higher probable upside, analysts clearly believe Omeros is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Omeros 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.83

Does the media refer more to CPIX or OMER?

In the previous week, Cumberland Pharmaceuticals and Cumberland Pharmaceuticals both had 3 articles in the media. Omeros' average media sentiment score of 0.88 beat Cumberland Pharmaceuticals' score of 0.00 indicating that Omeros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Omeros 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Omeros (OMER) Competitors

$10.48 +0.15 (+1.45%)

Closing price 04:00 PM Eastern

Extended Trading

$10.50 +0.01 (+0.14%)

As of 07:53 PM Eastern

Compare

OMER vs. NKTR, PRGO, PCRX, ASMB, and CPIX

Should you buy Omeros stock or one of its competitors? MarketBeat compares Omeros with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Omeros include Nektar Therapeutics (NKTR), Perrigo (PRGO), Pacira BioSciences (PCRX), Assembly Biosciences (ASMB), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "pharmaceuticals" industry.

How does Omeros compare to Nektar Therapeutics?

Omeros (NASDAQ:OMER) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

In the previous week, Nektar Therapeutics had 6 more articles in the media than Omeros. MarketBeat recorded 9 mentions for Nektar Therapeutics and 3 mentions for Omeros. Omeros' average media sentiment score of 0.88 beat Nektar Therapeutics' score of 0.66 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omeros currently has a consensus price target of $40.33, indicating a potential upside of 284.86%. Nektar Therapeutics has a consensus price target of $149.63, indicating a potential upside of 124.36%. Given Omeros' stronger consensus rating and higher possible upside, research analysts plainly believe Omeros is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Omeros has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	14.97
Nektar Therapeutics	$55.23M	40.80	-$164.08M	-$8.42	N/A

Omeros has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

48.8% of Omeros shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 10.5% of Omeros shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Nektar Therapeutics' return on equity of -85.40% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

Summary

Omeros beats Nektar Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Omeros compare to Perrigo?

Omeros (NASDAQ:OMER) and Perrigo (NYSE:PRGO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Omeros currently has a consensus target price of $40.33, indicating a potential upside of 284.86%. Perrigo has a consensus target price of $19.33, indicating a potential upside of 103.51%. Given Omeros' stronger consensus rating and higher possible upside, research analysts clearly believe Omeros is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

48.8% of Omeros shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 10.5% of Omeros shares are owned by company insiders. Comparatively, 0.4% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Perrigo	-43.50%	9.96%	3.90%

Omeros has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

In the previous week, Omeros had 2 more articles in the media than Perrigo. MarketBeat recorded 3 mentions for Omeros and 1 mentions for Perrigo. Omeros' average media sentiment score of 0.88 beat Perrigo's score of -0.26 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Omeros has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	14.97
Perrigo	$4.25B	0.31	-$1.43B	-$13.10	N/A

Summary

Omeros beats Perrigo on 13 of the 16 factors compared between the two stocks.

How does Omeros compare to Pacira BioSciences?

Omeros (NASDAQ:OMER) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Omeros presently has a consensus target price of $40.33, indicating a potential upside of 284.86%. Pacira BioSciences has a consensus target price of $29.40, indicating a potential upside of 25.05%. Given Omeros' stronger consensus rating and higher possible upside, equities analysts clearly believe Omeros is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Pacira BioSciences has a net margin of 0.70% compared to Omeros' net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Pacira BioSciences	0.70%	10.24%	5.47%

In the previous week, Omeros had 3 more articles in the media than Pacira BioSciences. MarketBeat recorded 3 mentions for Omeros and 0 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.67 beat Omeros' score of 0.88 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Omeros	Positive
Pacira BioSciences	Very Positive

Pacira BioSciences has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	14.97
Pacira BioSciences	$726.41M	1.27	$7.03M	$0.12	195.92

48.8% of Omeros shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 10.5% of Omeros shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Omeros has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Summary

Omeros and Pacira BioSciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Omeros compare to Assembly Biosciences?

Assembly Biosciences (NASDAQ:ASMB) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Assembly Biosciences currently has a consensus price target of $44.00, indicating a potential upside of 64.18%. Omeros has a consensus price target of $40.33, indicating a potential upside of 284.86%. Given Omeros' stronger consensus rating and higher possible upside, analysts plainly believe Omeros is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 5.1% of Assembly Biosciences shares are held by company insiders. Comparatively, 10.5% of Omeros shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Assembly Biosciences has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Omeros has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market.

Omeros has a net margin of 0.00% compared to Assembly Biosciences' net margin of -8.98%. Assembly Biosciences' return on equity of -4.21% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Omeros	N/A	-102.16%	64.87%

In the previous week, Omeros had 2 more articles in the media than Assembly Biosciences. MarketBeat recorded 3 mentions for Omeros and 1 mentions for Assembly Biosciences. Omeros' average media sentiment score of 0.88 beat Assembly Biosciences' score of -1.00 indicating that Omeros is being referred to more favorably in the news media.

Company	Overall Sentiment
Assembly Biosciences	Negative
Omeros	Positive

Omeros has lower revenue, but higher earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	5.89	-$6.12M	-$0.11	N/A
Omeros	N/A	N/A	-$3.35M	$0.70	14.97

Summary

Omeros beats Assembly Biosciences on 13 of the 16 factors compared between the two stocks.

How does Omeros compare to Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

In the previous week, Cumberland Pharmaceuticals and Cumberland Pharmaceuticals both had 3 articles in the media. Omeros' average media sentiment score of 0.88 beat Cumberland Pharmaceuticals' score of 0.00 indicating that Omeros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omeros	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omeros has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Cumberland Pharmaceuticals' return on equity of -12.01% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
Omeros	N/A	-102.16%	64.87%

Cumberland Pharmaceuticals has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Omeros has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market.

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 10.5% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cumberland Pharmaceuticals has higher revenue and earnings than Omeros. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	1.96	-$2.84M	-$0.49	N/A
Omeros	N/A	N/A	-$3.35M	$0.70	14.97

Omeros has a consensus target price of $40.33, indicating a potential upside of 284.86%. Given Omeros' stronger consensus rating and higher probable upside, analysts clearly believe Omeros is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

Omeros beats Cumberland Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Omeros News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMER vs. The Competition

Export

Metric	Omeros	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$747.64M	$8.08B	$6.45B	$12.39B
Dividend Yield	N/A	2.60%	2.69%	5.83%
P/E Ratio	14.97	15.24	24.92	23.97
Price / Sales	N/A	6.99	528.81	109.59
Price / Cash	5.52	16.83	44.82	54.51
Price / Book	-6.13	3.21	10.79	6.50
Net Income	-$3.35M	$226.25M	$3.56B	$336.88M
7 Day Performance	10.55%	-3.57%	1.67%	-0.22%
1 Month Performance	-8.55%	-3.72%	0.43%	0.77%
1 Year Performance	228.53%	1.93%	32.84%	31.57%

Omeros Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMER Omeros	3.7757 of 5 stars	$10.48 +1.5%	$40.33 +284.9%	+221.8%	$747.64M	N/A	14.97	210
NKTR Nektar Therapeutics	2.7144 of 5 stars	$61.15 +3.0%	$149.63 +144.7%	+672.0%	$2.01B	$55.23M	N/A	220	News Coverage
PRGO Perrigo	3.79 of 5 stars	$10.71 -2.6%	$19.33 +80.6%	-63.8%	$1.52B	$4.25B	N/A	8,100
PCRX Pacira BioSciences	4.2147 of 5 stars	$22.74 -1.1%	$29.40 +29.3%	-6.3%	$904.61M	$726.41M	189.52	720
ASMB Assembly Biosciences	2.0427 of 5 stars	$23.34 +1.7%	$44.00 +88.5%	+44.6%	$364.89M	$72.30M	N/A	100	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMER) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omeros (OMER) Competitors

OMER vs. NKTR, PRGO, PCRX, ASMB, and CPIX

How does Omeros compare to Nektar Therapeutics?

Summary

How does Omeros compare to Perrigo?

Summary

How does Omeros compare to Pacira BioSciences?

Summary

How does Omeros compare to Assembly Biosciences?

Summary

How does Omeros compare to Cumberland Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMER vs. The Competition

Omeros Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omeros (OMER) Competitors

OMER vs. NKTR, PRGO, PCRX, ASMB, and CPIX

How does Omeros compare to Nektar Therapeutics?

Does the media favor OMER or NKTR?

Do analysts prefer OMER or NKTR?

Which has higher earnings & valuation, OMER or NKTR?

Which has more risk and volatility, OMER or NKTR?

Do insiders & institutionals believe in OMER or NKTR?

Is OMER or NKTR more profitable?

Summary

How does Omeros compare to Perrigo?

Do analysts rate OMER or PRGO?

Do insiders and institutionals believe in OMER or PRGO?

Is OMER or PRGO more profitable?

Which has more volatility & risk, OMER or PRGO?

Does the media prefer OMER or PRGO?

Which has preferable earnings and valuation, OMER or PRGO?

Summary

How does Omeros compare to Pacira BioSciences?

Do analysts prefer OMER or PCRX?

Is OMER or PCRX more profitable?

Does the media favor OMER or PCRX?

Which has higher valuation and earnings, OMER or PCRX?

Do institutionals and insiders believe in OMER or PCRX?

Which has more risk and volatility, OMER or PCRX?

Summary

How does Omeros compare to Assembly Biosciences?

Do analysts prefer ASMB or OMER?

Do insiders and institutionals have more ownership in ASMB or OMER?

Which has more volatility and risk, ASMB or OMER?

Is ASMB or OMER more profitable?

Does the media refer more to ASMB or OMER?

Which has preferable earnings & valuation, ASMB or OMER?

Summary

How does Omeros compare to Cumberland Pharmaceuticals?

Does the media refer more to CPIX or OMER?

Is CPIX or OMER more profitable?

Which has more risk and volatility, CPIX or OMER?

Do insiders & institutionals have more ownership in CPIX or OMER?

Which has better earnings & valuation, CPIX or OMER?

Do analysts recommend CPIX or OMER?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMER vs. The Competition

Omeros Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools